Clinical trials: Schizophrenia
Schizophrenia, Catatonic, Schizophrenia, Disorganized
Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone
The purpose of this study is to evaluate the efficacy, tolerability and safety of patients on long-acting Risperidone microshpheres injection.
- Conditions
- Schizophrenia, Catatonic, Schizophrenia, Disorganized, Schizophrenia, Paranoid, Schizophrenia
- Trial name
- NCT00563017
- Testing
- Long-acting Risperidone microspheres injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hospital Authority, Hong Kong
Schizophrenia, Bipolar Episodes
Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study
The aim of the study is to describe patient characteristics (demographic and clinical) and the patterns of use of Quetiapine XR in patients receiving the drug for the first time in real-life practice regardless the final…
- Trial name
- NCT01689389
- Where
- 19 sites in France
- Volunteers
- 2,292 people
- Sponsor
- AstraZeneca
Schizophrenia
A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia
The purpose of this study is to evaluate the effects of the amino acid supplement N-Acetylcysteine versus placebo on working memory and other cognitive functions in persons with a diagnosis of schizophrenia.
- Trial name
- NAC (NCT01232790)
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Yale University
Dopamine Receptor Occupancy, Medication Satisfaction
Validation of Receptor Occupancy Simulation
To estimate dopamine receptor occupancy by aripiprazole using computer simulation To measure dopamine receptor occupancy by aripiprazole in patients treated with the antipsychotics To validate the simulation result by comparing…
- Conditions
- Dopamine Receptor Occupancy, Medication Satisfaction, Prolactin Level, Schizophrenia
- Trial name
- NCT01660880
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Seoul National University Hospital
Schizophrenia
Structural and Functional Correlates of Clinical Response to rTMS Treatment in Schizophrenia Patients With Resistant Auditory Hallucinations
The potential of non-invasive Transcranial Magnetic Stimulation (TMS) as a therapeutic tool for improving schizophrenic symptoms, in particular resistant hallucinations, has been increasingly studied over the past decades.
- Trial name
- TMSCCS (NCT02755623)
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre hospitalier de Ville-Evrard, France
Mindfulness Training
MBRS-Based Psychoeducation in Patients With Schizophrenia
This study aimed to determine the effects of mindfulness-based stress reduction training on anger management and functional recovery in patients with schizophrenia.
- Trial name
- NCT07130227
- Testing
- Session 1: Preparatory Session, Session 2: Mindfulness, Session 3: Our Perspectives on Ourselves and the World
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Ataturk University
Schizophrenia, Schizoaffective Disorder
Cognitive Remediation and Functional Skills Training in Schizophrenia
This randomized trial is examining whether a treatment called cognitive remediation is more effective when it is paired with a social and functional skills training component.
- Trial name
- NCT01175642
- Testing
- Cognitive Remediation, FAST
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- National Alliance for Research on Schizophrenia and Depression
Schizophrenia
Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia
Background: Bexarotene (Targretin) is a synthetic retinoid mainly used for treatment of patients suffer from oncological or dermatological diseases.
- Trial name
- NCT00535574
- Testing
- Bexarotene (Targretin LGD1069), bexarotene
- Where
- 3 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Beersheva Mental Health Center
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia
Observational, short-term prospective, multicenter study to assess psychometric properties of the Spanish version of SWN-K scale in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- SWN-K (NCT00749970)
- Where
- 14 sites in Spain
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Patients With Chronic Schizophrenia
The Effectiveness of Lower Extremity Strength Training
The increase in chronic schizophrenia patients with sarcopenia is currently an important healthcare issue in Taiwan and requires enhanced prevention and progress.
- Trial name
- LEST-CSchizo (NCT07183969)
- Testing
- lower limb muscle strength training program
- Where
- Taiwan
- Volunteers
- 78 people
- Sponsor
- National Taipei University of Nursing and Health Sciences
Relapse Schizophrenia
A RCT Study in Schizophrenia Relapse Prevention
THE AIM OF THE PROJECT The main aim lies in the prevention of frequent relapses typical for schizophrenia and schizoaffective disorder by means of simple, highly cost-effective information technology-aided approach RESEARCH…
- Trial name
- NCT01885923
- Testing
- ITAREPS
- Where
- Czechia
- Volunteers
- 150 people
- Sponsor
- Prague Psychiatric Center
Agitation, Schizophrenia
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia.
- Conditions
- Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder
- Trial name
- SERENITY I (NCT04268303)
- Testing
- Sublingual film containing dexmedetomidine (BXCL501)
- Where
- 15 sites in United States
- Volunteers
- 380 people
- Sponsor
- BioXcel Therapeutics Inc
Early Psychosis, Delusions
Intervention to Improve Coping With Negative Emotions in Patients With Psychosis (Feel-Good-Study)
The aim of the present single-centered pre-post study is to assess the feasibility and to investigate the putative efficacy of an emotion-oriented group intervention for patients with psychosis.
- Conditions
- Early Psychosis, Delusions, Emotional Distress, Self Esteem
- Trial name
- NCT04592042
- Testing
- Feel-Good- Group
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Philipps University Marburg
Schizophrenia
An Evaluation of a Psychoeducation Program in Individuals Diagnosed With Schizophrenia
This study was conducted to explore the effect on social functionality of the psychoeducation program organized to guide individuals diagnosed with schizophrenia to identifying and recognize emotions in facial expressions.
- Trial name
- NCT03865186
- Testing
- Psychoeducation Program, no intervention
- Volunteers
- 42 people
- Sponsor
- Kırıkkale University
Alzheimer Disease, Psychotic Disorders
Antipsychotic Discontinuation in Alzheimer's Disease
In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established.
- Conditions
- Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
- Trial name
- ADAD (NCT00417482)
- Testing
- risperidone
- Where
- 7 sites in United States
- Volunteers
- 180 people
- Sponsor
- New York State Psychiatric Institute
Psychotic Disorder
The Effect of D-serine as add-on Therapy in Recent-onset Psychosis
In psychotic disorders, negative symptoms and cognitive impairment are difficult to treat with antipsychotics, which are mostly effective for positive symptoms.
- Trial name
- DROP (NCT04140773)
- Testing
- D-serine
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Dragos Inta
Schizophrenia
Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia
This is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment, and 4 weeks safety follow-up.
- Trial name
- NCT00404573
- Testing
- RGH-188
- Where
- United States
- Volunteers
- 375 people
- Sponsor
- Forest Laboratories
Childhood Onset Psychotic Disorders, Schizophrenia
Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia
This study will test whether transcranial direct current stimulation (TDCS) can be used safely in children with schizophrenia and if it can improve memory and attention span or auditory hallucinations in these children, at least…
- Conditions
- Childhood Onset Psychotic Disorders, Schizophrenia, Psychosis, Mental Disorders
- Trial name
- NCT00757497
- Testing
- Electrical Polarization
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenias, Psychoses
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
Both GlyT-1 inhibitors and NMDA-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia patients.
- Conditions
- Schizophrenias, Psychoses, Psychotic Disorders, Schizophrenic Disorders
- Trial name
- NCT00491569
- Testing
- Sarcosine and D-serine
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- China Medical University Hospital